Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to either FOLFIRI ( irinotecan 180 mg/m ( 2 ) day 1 , LV 100 mg/m ( 2 ) as 2 h infusion and 5-FU 400 mg/m ( 2 ) as bolus , days 1 and 2 followed by 600 mg/m ( 2 ) / day as 22 h continuous infusion , q14 for four cycles ) followed by docetaxel 75 mg/m ( 2 ) day 1 , cisplatin 75 mg/m ( 2 ) day 1 , q21 for three cycles ( sequential arm ) or De Gramont regimen ( 5-FU/LV arm ) .